Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision

阐明HER2阴性、超低表达和低表达乳腺癌的临床病理学和基因组学特征:深入了解活检和手术切除诊断结果不一致的原因

阅读:1

Abstract

This study aimed to evaluate the representativeness of HER2-low and ultralow status in core needle biopsies (CNB) with AI assistance and investigate the clinicopathological and molecular characteristics of HER2-ultralow, HER2-null, and HER2-low breast cancer patients in the Chinese population. CNB-surgical excision biopsy (SEB) concordance was high between HER2-null and ultralow/low groups but limited in the ultralow subgroup. Univariate analyses showed that TNBC subtype, HR negative expression, high Ki-67 index, and AR negative expression were potential indicative factors for the discordance of HER2 status between CNB and SEB. Clinicopathological features showed no significant differences between low and ultralow groups. Genomic analysis revealed subtle mutation pattern differences. The HER2 copy number level did not show additional value in distinguishing subgroups. Conclusions highlight the need to address CNB-SEB diagnostic discordance, particularly in ultralow cases, emphasizing the necessity of HER2 retesting in surgical specimens.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。